![Luiz Belardinelli](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Luiz Belardinelli
Chief Tech/Sci/R&D Officer at InCarda Therapeutics, Inc.
Luiz Belardinelli active positions
Companies | Position | Start | End |
---|---|---|---|
InCarda Therapeutics, Inc.
![]() InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Chief Tech/Sci/R&D Officer | 05/04/2016 | - |
Career history of Luiz Belardinelli
Former positions of Luiz Belardinelli
Companies | Position | Start | End |
---|---|---|---|
CV Therapeutics, Inc.
![]() CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Corporate Officer/Principal | - | 02/05/2011 |
Statistics
International
United States | 3 |
Operational
Corporate Officer/Principal | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sectoral
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
CV Therapeutics, Inc.
![]() CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
InCarda Therapeutics, Inc.
![]() InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Health Technology |
- Stock Market
- Insiders
- Luiz Belardinelli
- Experience